Indian drug shares declined Wednesday following US President Trump's tariff announcement. These proposed tariffs will significantly impact companies with substantial US revenue exposure. Analysts suggest investors should now focus on domestically oriented Indian pharmaceutical firms. The Nifty Pharma index saw a notable decrease, while the benchmark Nifty 50 also fell. Negotiations are expected given India's vital role in supplying affordable medicines to the US.

Maruti Suzuki’s price hike, Anant Raj demerger, Aurobindo Pharma getting nod for bio similar, Anupam Rasayn open offer to Bliss GVS shareholders

In 2025, India exported USD 9.7 billion worth of pharmaceuticals to the US, accounting for 38 per cent of its total global pharma exports of USD 25.8 billion. | India News

Trump announces a tariff timeline for generic drugs, starting with zero tariffs for a year, then escalating to 200%.

Pharma stocks fall as Aurobindo Pharma drops over 4% following Trump's tariff announcement on imported generic medicines.

President Donald Trump has given generic drugmakers two years to shift manufacturing to the US or face 100% import tariffs from August 2028, rising to 200% a year later. The move…

US President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could put pressure on India's pharmaceutical exporters, but the country's cost advantage…

Donald Trump's proposed up to 200% tariff on generic drug imports has raised concerns for Indian pharma companies, but industry experts say the long-term impact may be limited.…

US tariff threats lead to a 1.4% drop in Nifty Pharma, with Lupin and Auropharma experiencing significant declines.